Company identity
Company number 02991879
Company profile
UK company 02991879, incorporated on 18 November 1994.
LGC Group - LGC Group
LGC Group is a global leader in the life sciences sector; our scientific tools and solutions are essential to our customers goals.
Company number 02991879
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
CH01 | Transaction MzUzODc1ODM3MWFkaXF6a2N4
Published 14 Aug 2026 13:48
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Apr 2026 to 30 Jun 2026
This project will pioneer a new approach to making viral vectors --- the essential building blocks for many advanced therapies --- by combining precision small-scale manufacturing with world-class molecular measurement. It brings together BiologIC Technologies, developer of the Qudos personal biomanufacturing system, and the National Measurement Laborator...
1 Feb 2026 to 31 Jul 2026
Agroceutical Products Ltd is developing a reliable UK supply of **galanthamine**, a licensed medicine used to treat symptoms of Alzheimer's disease and found naturally in daffodils. Our main research project, **GalanCEAmine**, uses controlled-environment farming and a new extraction process to increase the amount of this valuable molecule we can obtain fr...
1 Feb 2026 to 31 Jul 2026
This A4I project will support Innovate-UK funding for development of a novel "**S**upra**M**olecular" **R**NA **T**herapeutic (**SMRT**) delivery system and flexible, scalable RNA-manufacturing process for the sustainable manufacture of biologic drugs. Combined, the material and process will reduce considerably the material-use and energy-costs compared t...
1 Sep 2024 to 30 Nov 2024
ProMake sets to represent a ground-breaking initiative aimed at revolutionising the landscape of diagnostic technologies through the development and validation of an innovative biosensor technology. This initiative is set to transform the way pathogens, including viruses and bacteria, are detected, making strides towards offering a rapid, sensitive, and c...
1 Sep 2024 to 28 Feb 2025
**Aqdot**, a young **UK-based** Chemtech company, has completed relevant regulatory approvals and is now accelerating scaling of a novel macrocyclic chemical, **cucurbit\[n\]uril**, "**CB\[n**\]". Cucurbit\[n\]urils are extremely effective "supramolecular hosts": they non-covalently bind a wide range of chemical "guests". Cucurbit\[n\]urils have potential...
1 Jul 2024 to 30 Jun 2027
Engineered nanoparticles have great application potential in fields such as medicine, sensing, catalysis, energy storage, and opto-electronics. The utility and performance of engineered nanoparticles is largely determined by their surface chemistry. However, documented standards to measure such surface chemistry and functionality do not currently exist. S...
1 Jun 2024 to 31 Aug 2024
Salient Labs Ltd is a UK-based biomedical diagnostics SME with a focus on microbiome analysis. Microbiomes are integral to an individual's health, and microbiome composition can be used to diagnose or predict the risk of disease. The oral microbiome has been implicated in both dental disease and systemic diseases such as diabetes and cancer. Disease diagn...
1 May 2024 to 31 Oct 2024
**Aqdot**, a young **UK-based company**, has completed all relevant regulatory and environmental hurdles and is now accelerating production and commercialisation of a novel macrocyclic chemical, **cucurbit\[n\]uril**, "**CB\[n**\]". Cucurbit\[n\]urils are extremely effective "supramolecular hosts": they non-covalently bind a wide range of chemical "guests...
1 Jan 2024 to 30 Jun 2024
This project will focus on developing a critical quality control (QC) method that will allow manufacturers to test and ensure the quality of an immune therapy (called BioThymus). The BioThymus therapy is designed to treat a life-threatening disease in infants. Children born without a thymus gland (called complete DiGeorge Syndrome or cDGS) have a poorly f...
1 Jan 2024 to 31 Mar 2024
Formaldehyde is a significant health risk, and International Agency for Research on Cancer (IARC) classifies formaldehyde as a human carcinogen. There are stringent formaldehyde exposure guidelines that exist for indoor air (80 ppb WHO) that can be even lower at the national level (e.g., France 8 ppb by 2023). People are exposed to formaldehyde from a var...
1 Jan 2024 to 30 Jun 2024
Circulating tumour DNA (ctDNA) sequencing of plasma samples is becoming commonplace in clinical oncology practice and holds the promise to revolutionise cancer disease diagnosis and management. This promise is impeded by poor standardisation of ctDNA sequencing workflows, particularly in the pre-analytical phase. Limited control materials are currently av...
1 Jan 2024 to 31 Mar 2024
RADWIPES is the brand name of a cleaning product developed by MDCO Ltd. RADWIPES have been developed specifically for radiation decontamination activities associated with the decommissioning cleanup operations of legacy buildings on UK nuclear licensed sites, many of which, fall under the umbrella of the N.D.A. - Nuclear Decommissioning Authority. The ini...